Huadong Medicine：Subsidiary ADC innovative drugClinical trial approved by the US FDA
September 23, 2025
Source: drugdu
183
On September 22, Huadong Medicine announced that its wholly-owned subsidiary, Zhongmei Huadong, received notification from the U.S. Food and Drug Administration (FDA) that Zhongmei Huadong's clinical trial application for HDM2017 for injection has been approved by the FDA for Phase I clinical trials in the United States for the treatment of advanced malignant solid tumors. HDM2017 for injection is a novel antibody-drug conjugate (ADC) targeting cadherin 17 (LI-cadherin).
Comment: The approval of the US clinical trial application for HDM2017 for injection marks another important step forward in the product's development and will further enhance Huadong Medicine 's core competitiveness in oncology treatment. However, clinical trials inherently carry risks and uncertainties, and investors should carefully monitor subsequent results.
https://finance.eastmoney.com/a/202509233520253862.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval December 12, 2025
- Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials December 12, 2025
- The ‘Sweetest’ HPV Vaccine Market is Gone | Haibin Interview December 12, 2025
- InnoCare Pharma announced that its first independently developed next-generation TRK inhibitor, zoletrazinib, has been approved for marketing in China December 12, 2025
- Is PD-1/VEGF dual antibody + ADC becoming the standard configuration? December 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
